A commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology. We develop, manufacture and sell the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally-invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States.
Lead Underwriter
BofA Securities, Inc, Goldman Sachs & Co. LLC
Co-Managers
Cowen and Company, Guggenheim Securities, LLC, SVB Leerink LLC